NSB
$40M42mo
Neuroscientific Biopharmaceuticals
Biotechnology · Neurology
Developing EmtinB, a metal-attenuating peptide for neurodegenerative diseases including Alzheimer's and motor neurone disease.
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.4M
Dec 2025 4C
Runway
42moSTABLE
Based on Dec 2025 4C
Market Cap
$40M
Burn Rate
$0.5M/qtr
Dec 2025 4C
Shares Outstanding
333M
Pipeline Assets
1
Latest Insight(1)
25 Feb 2026Half YearHalf Yearly Report and Accounts
Cash$6.4M·Burn$0.9M/q·OCF$-0.9M
3M Price
NSB.ASX$0.120-20.0% 3M
Low $0.071High $0.155
Pipeline Assets (1)
EmtinBAlzheimer's disease / MND
PreclinicalDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
EmtinB
Alzheimer's disease / MND
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (2)· 1 upcoming · 1 past
StemSmart Phase 2 Crohns disease trial initiation
UpcomingExpectedarrow_upwardHigh31 Dec 2026
expand_more1 past catalyst
ConfirmedremoveMed12 Jan 2026
3 of 4 patients (75%) in Cohort 1 achieved a successful Clinical Response, defined as closure of ≥50% of fistula openings or a decrease in fistula discharge of ≥50%. The 4th patient demonstrated a partial response with improvement, and further clinical assessments are ongoing. These results were achieved under the TGA Special Access Scheme Category B pathway in patients with limited effective treatment alternatives.
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 1 of 1 4Cs on time· statutory deadline
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.